{
    "clinical_study": {
        "@rank": "166339", 
        "arm_group": {
            "arm_group_label": "Degarelix", 
            "description": "adult male patients with advanced hormone dependent prostate cancer who receive 240 mg as a start dose and then monthly 80mg Firmagon\u00ae for one year"
        }, 
        "brief_summary": {
            "textblock": "How are testosterone levels of patients with prostate cancer under treatment with Firmagon\u00ae\n      changing.\n\n      Former studies showed a quick fall of testosterone levels after start of therapy with\n      Firmagon\u00ae and a quick recovery when therapy is stopped. The investigators want to prove this\n      in a normal outpatient urologist setting. Furthermore data is collected to prove the\n      adherence to the German S3-Guideline for the treatment of prostate cancer."
        }, 
        "brief_title": "Treatment of Prostate Cancer With Firmagon\u00ae", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  advanced hormone-dependent prostate cancer with no other previous hormone therapy for\n             whom - irrespectively of this NIS -the use of Firmagon\u00ae is intended\n\n        Exclusion Criteria:\n\n          -  contraindication for Degarelix"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "95 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "adult male patients of outpatient urological medical practice"
            }
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01710098", 
            "org_study_id": "UCM12-01"
        }, 
        "intervention": {
            "arm_group_label": "Degarelix", 
            "description": "subcutaneous injection", 
            "intervention_name": "Degarelix", 
            "intervention_type": "Drug", 
            "other_name": "Firmagon\u00ae"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "testosterone", 
            "S3-Adherence", 
            "Quality of Life"
        ], 
        "lastchanged_date": "October 16, 2012", 
        "location": {
            "contact": {
                "email": "Buchsteiner@ukmp.de", 
                "last_name": "Karin Buchsteiner", 
                "phone": "+49-89-85693-0", 
                "phone_ext": "2525"
            }, 
            "contact_backup": {
                "email": "F\u00f6rster@ukmp.de", 
                "last_name": "Stefanie F\u00f6rster", 
                "phone": "+49-89-85693-0", 
                "phone_ext": "2500"
            }, 
            "facility": {
                "address": {
                    "city": "Planegg", 
                    "country": "Germany", 
                    "state": "Bavaria", 
                    "zip": "82152"
                }, 
                "name": "UCM GmbH"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_groups": "1", 
        "official_title": "Effectiveness and Safety as Well as Adherence of the \"S3 Guidelines for the Treatment of Prostate Cancer\" in the Treatment of Patients of Patients With Firmagon\u00ae", 
        "overall_contact": {
            "email": "Durner@ukmp.de", 
            "last_name": "Leopold Durner, MD", 
            "phone": "+49-89-85693-0", 
            "phone_ext": "2569"
        }, 
        "overall_contact_backup": {
            "email": "Lang@ukmp.de", 
            "last_name": "Roland Lang, MD", 
            "phone": "+49-89-85693-0", 
            "phone_ext": "2543"
        }, 
        "overall_official": {
            "affiliation": "UCM GmbH", 
            "last_name": "Leopold Durner, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "PSA-/Testosterone Level", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "reference": [
            {
                "PMID": "2122011", 
                "citation": "Thompson IM, Zeidman EJ, Rodriguez FR. Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate. J Urol. 1990 Dec;144(6):1479-80. Review."
            }, 
            {
                "PMID": "19035858", 
                "citation": "Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, Jensen JK, Olesen TK, Schr\u00f6der FH. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008 Dec;102(11):1531-8."
            }, 
            {
                "PMID": "17698136", 
                "citation": "Morote J, Orsola A, Planas J, Trilla E, Ravent\u00f3s CX, Cecchini L, Catal\u00e1n R. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol. 2007 Oct;178(4 Pt 1):1290-5. Epub 2007 Aug 14."
            }, 
            {
                "PMID": "19747358", 
                "citation": "Perachino M, Cavalli V, Bravi F. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance? BJU Int. 2010 Mar;105(5):648-51. Epub 2009 Aug 28."
            }, 
            {
                "PMID": "16697805", 
                "citation": "Mariani S, Salvatori L, Basciani S, Arizzi M, Franco G, Petrangeli E, Spera G, Gnessi L. Expression and cellular localization of follicle-stimulating hormone receptor in normal human prostate, benign prostatic hyperplasia and prostate cancer. J Urol. 2006 Jun;175(6):2072-7; discussion 2077."
            }, 
            {
                "PMID": "20961245", 
                "citation": "Radu A, Pichon C, Camparo P, Antoine M, Allory Y, Couvelard A, Fromont G, Hai MT, Ghinea N. Expression of follicle-stimulating hormone receptor in tumor blood vessels. N Engl J Med. 2010 Oct 21;363(17):1621-30."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01710098"
        }, 
        "responsible_party": {
            "investigator_affiliation": "United Clinic Management GmbH", 
            "investigator_full_name": "Karin Buchsteiner", 
            "investigator_title": "Head of Study Group", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Percentage of patients who have been treated in accordance with the grade A recommendations of the S3 guideline for treatment of prostate cancer", 
                "measure": "S3 Guideline", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "QLQ-PR 25", 
                "measure": "Quality of Life", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Anxiety score", 
                "measure": "Anxiety", 
                "safety_issue": "No", 
                "time_frame": "12 Months"
            }, 
            {
                "description": "analog visual painscala", 
                "measure": "Pain", 
                "safety_issue": "No", 
                "time_frame": "12 Months"
            }
        ], 
        "source": "United Clinic Management GmbH", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "United Clinic Management GmbH", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "October 2012"
    }
}